Cargando…

Variation in adverse drug events of opioids in the United States

Background: The United States (US) ranks high, nationally, in opioid consumption. The ongoing increase in the misuse and mortality amid the opioid epidemic has been contributing to its rising cost. The worsening health and economic impact of opioid use disorder in the US warrants further attention....

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Edward Y., McCall, Kenneth L., Piper, Brian J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079914/ https://www.ncbi.nlm.nih.gov/pubmed/37033633 http://dx.doi.org/10.3389/fphar.2023.1163976

Ejemplares similares

Pronounced State-Level Disparities in Prescription of Cannabinoids to Medicaid Patients
por: Liu, Edward Y., et al.
Publicado: (2023)

Rise, and pronounced regional variation, in methylphenidate, amphetamine, and lisdexamfetamine distribution in the United States
por: Vaddadi, Sneha M., et al.
Publicado: (2021)

Declines and pronounced regional disparities in meperidine use in the United States
por: Boyle, John M., et al.
Publicado: (2021)

Exposure to chronic mild stress prevents kappa opioid-mediated reinstatement of cocaine and nicotine place preference
por: Al-Hasani, Ream, et al.
Publicado: (2013)

Dynamic changes in prescription opioids from 2006 to 2017 in Texas
por: Ighodaro, Ebuwa O., et al.
Publicado: (2019)

Evaluation of the Direct Costs of Managing Adverse Drug Events in all Ages and of Avoidable Adverse Drug Events in Older Adults in Japan
por: Katsuno, Hayato, et al.
Publicado: (2021)

Prescription Opioid Distribution after the Legalization of Recreational Marijuana in Colorado
por: Kropp Lopez, Amalie K., et al.
Publicado: (2020)

Association of Gabapentinoids With the Risk of Opioid-Related Adverse Events in Surgical Patients in the United States
por: Bykov, Katsiaryna, et al.
Publicado: (2020)

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system
por: Guo, Qiang, et al.
Publicado: (2022)

Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016
por: Piper, Brian J., et al.
Publicado: (2018)

Risk of major adverse events associated with gabapentinoid and opioid combination therapy: A systematic review and meta-analysis
por: Hahn, Jongsung, et al.
Publicado: (2022)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
por: Wang, Jun, et al.
Publicado: (2023)

Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance
por: Wakabayashi, Tomohito, et al.
Publicado: (2022)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
por: Jiao, Xue-Feng, et al.
Publicado: (2023)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

Hospitalizations Due to Adverse Drug Events in the Elderly—A Retrospective Register Study
por: Laatikainen, Outi, et al.
Publicado: (2016)

Vertebroplasty and kyphoplasty: a comparative review of efficacy and adverse events
por: McCall, Todd, et al.
Publicado: (2008)

Kratom Use Within the Context of the Evolving Opioid Crisis and the COVID-19 Pandemic in the United States
por: Prozialeck, Walter C., et al.
Publicado: (2021)

A Screening Test for HLA-B(∗)15:02 in a Large United States Patient Cohort Identifies Broader Risk of Carbamazepine-Induced Adverse Events
por: Fang, Hua, et al.
Publicado: (2019)

Analysis of Drug-Induced Gastrointestinal Obstruction and Perforation Using the Japanese Adverse Drug Event Report Database
por: Satake, Riko, et al.
Publicado: (2021)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Bai, Xiaoyin, et al.
Publicado: (2021)

Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
por: Zhang, Lin, et al.
Publicado: (2023)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
por: Guo, Haoning, et al.
Publicado: (2022)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

Neuropsychiatric Adverse Events of Montelukast: An Analysis of Real-World Datasets and drug−gene Interaction Network
por: Umetsu, Ryogo, et al.
Publicado: (2021)

Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
por: Zhang, Ying, et al.
Publicado: (2023)

Pharmacogenetics of pediatric acute lymphoblastic leukemia in Uruguay: adverse events related to induction phase drugs
por: Burgueño-Rodríguez, Gabriela, et al.
Publicado: (2023)

Drug Interactions With New Synthetic Opioids
por: Pérez-Mañá, Clara, et al.
Publicado: (2018)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
por: Guo, Haoning, et al.
Publicado: (2022)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

Nature of adverse events with opioids in hospitalised patients: a post-hoc analysis of three patient record review studies
por: Schutijser, Bernadette Clara Francisca Maria, et al.
Publicado: (2020)

Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system
por: Jeong, Eugene, et al.
Publicado: (2022)

Unprescribed and unnoticed: Retrospective chart review of adverse events of interactions between antidepressants and over-the-counter drugs
por: Woroń, Jarosław, et al.
Publicado: (2022)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2023)

Current landscape and tailored management of immune-related adverse events
por: Liu, Wenhui, et al.
Publicado: (2023)

Ontology-Based Classification and Analysis of Adverse Events Associated With the Usage of Chloroquine and Hydroxychloroquine
por: Ngai, Jamie, et al.
Publicado: (2022)

Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database
por: Zhou, Zhi-Xuan, et al.
Publicado: (2022)

Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects
por: Pauli, Christopher S., et al.
Publicado: (2020)

Predicting Adverse Drug Events in Chinese Pediatric Inpatients With the Associated Risk Factors: A Machine Learning Study
por: Yu, Ze, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vfcciivghq1nfor5g25a7rkhlq